A comparative phase 2 analysis of the BiCAR trial reports that accelerated glofitamab significantly prolongs survival after anti-CD19 CAR T-cell failure in diffuse large B-cell lymphoma. The study frames glofitamab as an effective bispecific salvage option for patients who have already exhausted CAR-T. The work matters for clinical decision-making because the post–CAR T landscape remains heavily constrained, and comparative survival outcomes against non-bispecific salvage therapies are often the most urgent questions. Overall, the update adds momentum to faster treatment ramp strategies for bispecifics, while reinforcing the need for head-to-head data in the CAR-refractory setting.
Get the Daily Brief